PremiumThe FlyAscendis Pharma price target raised to $260 from $254 at JPMorgan Ascendis Pharma Grants Employee Warrants to Foster Growth Ascendis Pharma A/S Q2 Earnings Call Highlights Growth PremiumThe FlyAscendis Pharma price target raised to $290 from $243 at Citi Ascendis Pharma price target raised to $295 from $289 at Wells Fargo Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments PremiumCompany AnnouncementsAscendis Pharma Reports Strong Q2 2025 Results and Advances Key Therapies Ascendis Pharma’s Clinical Trial Update: Implications for Investors Bullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating 
